Richard Pestell
CEO and Founder -ProstaGene, StromaGenesis, EcoGenome, ioROC, Shenandoah Pharmaceutical
Richard Pestell’s medical journey began at the University of Western Australia, where he graduated at the top of his class, earning an M.B., B.S. His early training included a physician-in-training experience at Royal Perth Hospital and St Vincent's Hospital, Sydney. During this period, he gained a busy, comprehensive grounding in Internal Medicine and residency, including oncology, endocrinology, hematology, cardiology, and transplant medicine, which helped establish both clinical discipline and long-term direction.
His growing interest in cancer biology led him to pursue advanced research, culminating in a Ph.D. from the University of Melbourne at the Howard Florey Institute, specializing in oncogene regulation of gene transcription. This work supported his understanding of how gene regulation relates to disease, and it strengthened the research skills that later informed his academic and leadership responsibilities.
Richard’s academic excellence was recognized through national scholarships and multiple competitive fellowships, including a Winthrop Fellowship and an NHMRC postgraduate award. These achievements led him to Harvard Medical School and Massachusetts General Hospital, where he trained further as a clinical and research fellow. Through those roles, he continued building experience in both medicine and research, with a commitment to translating knowledge into better care.
Academic Leadership and Scientific Influence
Richard Pestell continued his academic career at Northwestern University and then at the Albert Einstein College of Medicine. Over time, he became a Professor, the Chair of the Division of Endocrine-Dependent Tumor Biology, and the Co-Director of major cancer research programs. He also held appointments at multiple hospitals in New York, which helped him remain connected to patient care and medical education while he led research and academic initiatives.
He contributed research that helped inform modern cancer therapeutics. His research on cyclin D1 was cited in the seminal publications underpinning CDK inhibitor clinical trials and their adoption as a standard therapy for breast cancer globally. His work focused on scientific clarity and clinical relevance, aiming to support research that physicians and investigators could rely on.
His work on CCR5 further provided the scientific framework for current oncology clinical trials with CCR5 inhibitors. Throughout his career, he has published over 700 works, received more than 110,000 citations, and achieved an h-index of 162, along with extensive invited lecture engagements around the world. These outcomes reflect consistent research production and ongoing involvement in international scientific dialogue.
Directing Major Cancer Centers
Richard Pestell became the Director of the Lombardi Comprehensive Cancer Center at Georgetown University in 2002. He also served as Chair of the Department of Oncology and Associate Vice President at Georgetown University Medical Center. In this capacity, he was responsible for research, clinical operations, and faculty development, and he took part in institutional restructuring and growth to strengthen the cancer center’s capabilities.
He worked to build community partnerships, enhance research programs, and expand clinical services across Georgetown and MedStar systems. These efforts required coordination across multiple teams and priorities, with attention to sustainable results and the needs of patients and communities served by the health system.
Richard became the Director of the Sidney Kimmel Cancer Center in 2005. Also, he served as Chair of the Department of Cancer Biology and head of the Oncology Service Line at Thomas Jefferson University. These roles expanded his leadership responsibilities across clinical operations, research development, and program organization, supporting growth across cancer services and academic initiatives.
He later became the Executive Vice President, charged with enterprise-wide strategic decisions across a system of 30,000 employees. At Jefferson, he directed an overall cancer enterprise with an annual budget of> $350 m and led transformational efforts in clinical care, research infrastructure, regional expansion, and team building. The cancer center rose from 64th to 17th under his tenure, reflecting a period of measurable institutional progress.
Academic Appointments and Global Engagement
Richard Pestell has also held leadership roles in academia outside of the US and has supported initiatives that connect education with research and outreach. He was a founding Director of the Delaware Valley Institute for Clinical and Translational Science, helped develop new education pathways for historically black colleges, and led global cancer outreach at the International Network for Cancer Treatment and Research. These roles reflect a commitment to building collaborations and advancing training opportunities.
He has served on faculty or advisory boards with the University of Melbourne, the University of Western Australia, Nanyang Technological University, Xavier University School of Medicine, Kazan Federal University, and several European institutions. Through these affiliations, he contributed to academic planning, advisory work, and shared efforts that supported research development and education in multiple settings.
Richard has been elected to and served with prominent scientific bodies that reflect broad professional engagement. He has served at the Academia Europaea, the Hungarian Academy of Sciences, the American Society for Clinical Investigation, and the Royal Society of Biology, among others. His awards included the RD Wright Medallion and the Eric Susman Prize in Medicine, culminating in his being made an Officer of the Order of Australia in 2019.
Building Companies and Advancing Innovation
Richard Pestell has combined academic leadership with entrepreneurship across the biotechnology sector. He is the founder of six biotechnology companies: LightSeed, ProstaGene (acquired in 2018), EcoGenome, StromaGenesis, ioROC, and Shenandoah Pharmaceuticals. Along with these ventures, he has raised nearly 50 million dollars from investors and more than 80 million dollars as a principal investigator on NIH research grants, supporting both innovation and research.
His patent portfolio has included discoveries in molecular diagnostics, cancer prognostics, therapeutic methods, and novel technologies that have impacted academic and commercial drug discovery and development. He has served in advisory capacities for organizations such as the National Academy of Inventors, CytoDyn, Novartis, Deloitte, and numerous health technology companies. Through these roles, he has focused on translating research into practical tools and methods that support better outcomes.
Philanthropy, Community Service, and Cultural Engagement
Richard Pestell has made community work a central part of his professional life. At Georgetown and at Jefferson, he led philanthropic efforts that produced transformational gifts and created new ways to sustain ongoing fundraising in support of cancer care, wellness centers, and community outreach initiatives. These efforts strengthened resources for patient-centered programs and helped support broader community engagement in cancer education and care.
He has also served on different boards, including the National Museum of American Jewish History, the Chamber Orchestra of Philadelphia, the Jewish Federation of Greater Philadelphia, the Historic St. Peter’s Church Preservation Corporation, the American Cancer Society committees, and several university societies. His board service reflects ongoing engagement with cultural institutions, community organizations, and health-related initiatives.
Richard also supported the Olivia Newton-John Wellness Center through a fundraising trek on The Great Wall. This activity paired direct participation with fundraising goals and highlighted the importance of sustained support for wellness programs connected to cancer care.
A Continuing Commitment to Science and Human Health
Richard Pestell now serves as President of the Pennsylvania Cancer and Regenerative Medicine Center, Blumberg Distinguished Professor of Translational Medical Research at the Baruch Blumberg Institute, and a member of the Wistar Institute Cancer Center. He continues to support global cancer programs, mentor scientific leaders, and develop technologies for improved diagnostics and treatment, maintaining a focus on research translation and patient-centered impact.
He continues to apply scientific insight with a practical approach to enhance the quality of patient care and institutions, and to broaden the reach of modern oncology. Richard’s extensive work continues to influence cancer research, education, and biotechnology on a global scale through sustained leadership, ongoing research involvement, and continued commitment to collaboration.
Follow on: Bluesky
Books He Wrote or Contributed To:
Molecular Endocrinology: Basic Concepts and Clinical Correlations
Oncogenes
Cancer Epigenetics: Biomolecular Therapeutics in Human Cancer
Prostate Cancer: Signaling Networks, Genetics, and New Treatment Strategies
Molecular Targeting and Signal Transduction (Cancer Treatment and Research)
Signal Transduction Protocols
Molecular Targeting and Signal Transduction
Checkpoint Control Protocols: Methods in Molecular Biology
Methods in Enzymology
D-type Cyclins and Cancer
Hormonal Research Perspectives: Endocrine Interactions
Prostate Cancer: Signalling Networks, Genetics and New Treatment Strategies [Book Review]
Signal Transduction Based Mouse Models of Prostate Cancer
His growing interest in cancer biology led him to pursue advanced research, culminating in a Ph.D. from the University of Melbourne at the Howard Florey Institute, specializing in oncogene regulation of gene transcription. This work supported his understanding of how gene regulation relates to disease, and it strengthened the research skills that later informed his academic and leadership responsibilities.
Richard’s academic excellence was recognized through national scholarships and multiple competitive fellowships, including a Winthrop Fellowship and an NHMRC postgraduate award. These achievements led him to Harvard Medical School and Massachusetts General Hospital, where he trained further as a clinical and research fellow. Through those roles, he continued building experience in both medicine and research, with a commitment to translating knowledge into better care.
Academic Leadership and Scientific Influence
Richard Pestell continued his academic career at Northwestern University and then at the Albert Einstein College of Medicine. Over time, he became a Professor, the Chair of the Division of Endocrine-Dependent Tumor Biology, and the Co-Director of major cancer research programs. He also held appointments at multiple hospitals in New York, which helped him remain connected to patient care and medical education while he led research and academic initiatives.
He contributed research that helped inform modern cancer therapeutics. His research on cyclin D1 was cited in the seminal publications underpinning CDK inhibitor clinical trials and their adoption as a standard therapy for breast cancer globally. His work focused on scientific clarity and clinical relevance, aiming to support research that physicians and investigators could rely on.
His work on CCR5 further provided the scientific framework for current oncology clinical trials with CCR5 inhibitors. Throughout his career, he has published over 700 works, received more than 110,000 citations, and achieved an h-index of 162, along with extensive invited lecture engagements around the world. These outcomes reflect consistent research production and ongoing involvement in international scientific dialogue.
Directing Major Cancer Centers
Richard Pestell became the Director of the Lombardi Comprehensive Cancer Center at Georgetown University in 2002. He also served as Chair of the Department of Oncology and Associate Vice President at Georgetown University Medical Center. In this capacity, he was responsible for research, clinical operations, and faculty development, and he took part in institutional restructuring and growth to strengthen the cancer center’s capabilities.
He worked to build community partnerships, enhance research programs, and expand clinical services across Georgetown and MedStar systems. These efforts required coordination across multiple teams and priorities, with attention to sustainable results and the needs of patients and communities served by the health system.
Richard became the Director of the Sidney Kimmel Cancer Center in 2005. Also, he served as Chair of the Department of Cancer Biology and head of the Oncology Service Line at Thomas Jefferson University. These roles expanded his leadership responsibilities across clinical operations, research development, and program organization, supporting growth across cancer services and academic initiatives.
He later became the Executive Vice President, charged with enterprise-wide strategic decisions across a system of 30,000 employees. At Jefferson, he directed an overall cancer enterprise with an annual budget of> $350 m and led transformational efforts in clinical care, research infrastructure, regional expansion, and team building. The cancer center rose from 64th to 17th under his tenure, reflecting a period of measurable institutional progress.
Academic Appointments and Global Engagement
Richard Pestell has also held leadership roles in academia outside of the US and has supported initiatives that connect education with research and outreach. He was a founding Director of the Delaware Valley Institute for Clinical and Translational Science, helped develop new education pathways for historically black colleges, and led global cancer outreach at the International Network for Cancer Treatment and Research. These roles reflect a commitment to building collaborations and advancing training opportunities.
He has served on faculty or advisory boards with the University of Melbourne, the University of Western Australia, Nanyang Technological University, Xavier University School of Medicine, Kazan Federal University, and several European institutions. Through these affiliations, he contributed to academic planning, advisory work, and shared efforts that supported research development and education in multiple settings.
Richard has been elected to and served with prominent scientific bodies that reflect broad professional engagement. He has served at the Academia Europaea, the Hungarian Academy of Sciences, the American Society for Clinical Investigation, and the Royal Society of Biology, among others. His awards included the RD Wright Medallion and the Eric Susman Prize in Medicine, culminating in his being made an Officer of the Order of Australia in 2019.
Building Companies and Advancing Innovation
Richard Pestell has combined academic leadership with entrepreneurship across the biotechnology sector. He is the founder of six biotechnology companies: LightSeed, ProstaGene (acquired in 2018), EcoGenome, StromaGenesis, ioROC, and Shenandoah Pharmaceuticals. Along with these ventures, he has raised nearly 50 million dollars from investors and more than 80 million dollars as a principal investigator on NIH research grants, supporting both innovation and research.
His patent portfolio has included discoveries in molecular diagnostics, cancer prognostics, therapeutic methods, and novel technologies that have impacted academic and commercial drug discovery and development. He has served in advisory capacities for organizations such as the National Academy of Inventors, CytoDyn, Novartis, Deloitte, and numerous health technology companies. Through these roles, he has focused on translating research into practical tools and methods that support better outcomes.
Philanthropy, Community Service, and Cultural Engagement
Richard Pestell has made community work a central part of his professional life. At Georgetown and at Jefferson, he led philanthropic efforts that produced transformational gifts and created new ways to sustain ongoing fundraising in support of cancer care, wellness centers, and community outreach initiatives. These efforts strengthened resources for patient-centered programs and helped support broader community engagement in cancer education and care.
He has also served on different boards, including the National Museum of American Jewish History, the Chamber Orchestra of Philadelphia, the Jewish Federation of Greater Philadelphia, the Historic St. Peter’s Church Preservation Corporation, the American Cancer Society committees, and several university societies. His board service reflects ongoing engagement with cultural institutions, community organizations, and health-related initiatives.
Richard also supported the Olivia Newton-John Wellness Center through a fundraising trek on The Great Wall. This activity paired direct participation with fundraising goals and highlighted the importance of sustained support for wellness programs connected to cancer care.
A Continuing Commitment to Science and Human Health
Richard Pestell now serves as President of the Pennsylvania Cancer and Regenerative Medicine Center, Blumberg Distinguished Professor of Translational Medical Research at the Baruch Blumberg Institute, and a member of the Wistar Institute Cancer Center. He continues to support global cancer programs, mentor scientific leaders, and develop technologies for improved diagnostics and treatment, maintaining a focus on research translation and patient-centered impact.
He continues to apply scientific insight with a practical approach to enhance the quality of patient care and institutions, and to broaden the reach of modern oncology. Richard’s extensive work continues to influence cancer research, education, and biotechnology on a global scale through sustained leadership, ongoing research involvement, and continued commitment to collaboration.
Follow on: Bluesky
Books He Wrote or Contributed To:
Molecular Endocrinology: Basic Concepts and Clinical Correlations
Oncogenes
Cancer Epigenetics: Biomolecular Therapeutics in Human Cancer
Prostate Cancer: Signaling Networks, Genetics, and New Treatment Strategies
Molecular Targeting and Signal Transduction (Cancer Treatment and Research)
Signal Transduction Protocols
Molecular Targeting and Signal Transduction
Checkpoint Control Protocols: Methods in Molecular Biology
Methods in Enzymology
D-type Cyclins and Cancer
Hormonal Research Perspectives: Endocrine Interactions
Prostate Cancer: Signalling Networks, Genetics and New Treatment Strategies [Book Review]
Signal Transduction Based Mouse Models of Prostate Cancer
